TELEFLEX INCORPORATED (NYSE:TFX) Files An 8-K Other Events
Item 8.01. Other Events.
On February 26, 2019, Benson F. Smith, Chairman of the Board of Directors of Teleflex Incorporated (the “Company”), entered into a stock trading plan (the “Plan”) in accordance with Rule10b5‑1 under the Securities Exchange Act of 1934, as amended. Under Rule10b5‑1, directors, officers and other employees who are not in possession of material nonpublic information may adopt prearranged plans or contracts for the sale of Company securities under specified conditions and at specified times. Mr. Smith has advised the Company that he entered into the Plan in connection with his retirement financial planning.
The Plan provides for the sale of up to a total of 110,481 shares of the Company’s common stock, which will be acquired through the exercise of stock options currently held by Mr. Smith. The total number of shares that may be sold under the Plan represents approximately 19% of Mr. Smith total holdings of the Company’s common stock, which include, for purposes of this computation, direct shares and shares underlying (i) vested restricted stock units for which Mr. Smith has elected to defer delivery, (ii) unvested restricted stock units and (iii) vested and unvested options to purchase the Company’s common stock.
Sales under the Plan are scheduled to take place periodically beginning in March 2019 and ending in July 2019. Any shares that are sold under the Plan will be sold on the open market, subject to minimum price thresholds specified in the Plan.
The Company does not undertake to report Rule 10b5-1 plans that may be adopted by any officers or directors in the future, or to report any modifications or termination of any publicly announced trading plan, except to the extent required by law.
About TELEFLEX INCORPORATED (NYSE:TFX)
Teleflex Incorporated is a provider of medical technology products. The Company designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for diagnostic and therapeutic procedures in critical care and surgical applications. The Company markets and sells its products to hospitals and healthcare providers, across the world, through a combination of its direct sales force and distributors. The Company operates through six segments: Vascular North America; Anesthesia North America; Surgical North America; Europe, the Middle East and Africa (EMEA); Asia, and Original Equipment Manufacturer (OEM). The Company manufactures its products at approximately 30 manufacturing sites, with manufacturing operations located in the Czech Republic, Germany, Malaysia, Mexico and the United States. The Company’s all others businesses include single-use respiratory, urology and cardiac care products, as well as capital equipment.
